Results 191 to 200 of about 255,199 (267)

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

MeCP2 requires interactions with nucleosome linker DNA to read chromatin DNA methylation. [PDF]

Nat Commun
Watson JA, Alexander-Howden BK, Hall TS, Wear MA, McGhie F, Clifford G, Wapenaar H, Zou J, Bird A, Wilson MD.   +9 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Elevating Haloperoxidase Expression in Escherichia coli through Fusion with a Formate Oxidase. [PDF]

Chembiochem
Pothuizen A, van Hengst JMA, Wever R, Hagedoorn PL, Hollmann F.   +4 more
europepmc   +1 more source

Astrocyte heterogeneity in brain metastases

Molecular Oncology, EarlyView.
Astrocytes emerge as pivotal regulators of metastatic colonization, survival, immune remodeling, and therapy response associated with an increasing heterogeneity that requires spatially and longitudinally resolved approaches to uncover regulatory programs and guide context‐specific therapies.
Carolina Hernández‐Oliver, Neibla Priego, Manuel Valiente   +2 more
wiley   +1 more source

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. [PDF]

Front Immunol
Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, He P, Liu R, Zhang J, Wang K, Han R, Huangfu H.   +11 more
europepmc   +1 more source

Mechanistic Insights Into Nitric Oxide Capture and Release in a Radical-Scavenging Zinc Ascorbate Metal-Organic Framework. [PDF]

Small Sci
Tajnšek TK, Djinović P, Huš M, Likozar B, Lopes MP, Carvalho S, Batista M, Pinto ML, Pires J, Kavak S, Bals S, Caserman S, Zabukovec Logar N, Mazaj M.   +13 more
europepmc   +1 more source

Correction to "Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity". [PDF]

Bioconjug Chem
Aoyama M, Tada M, Yokoo H, Ito T, Misawa T, Demizu Y, Ishii-Watabe A.   +6 more
europepmc   +1 more source

Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologies. [PDF]

Drug Deliv
Feng C, Lou R, Chen S, Lin F, Ge J, Zhang Y, Lin C, Huang C.   +7 more
europepmc   +1 more source

Linker Chemistry in Radiopharmaceutical Design. [PDF]

Bioconjug Chem
Stoddard A, Furey K, Dehlavi G, Mane MM, Sebastiano J, Zeglis BM.   +5 more
europepmc   +1 more source